SCHEMBL7977879

SCHEMBL7977879

CC(C)(Oc1ccc(C(F)(F)F)cc1)c1nnc(-c2cnccc2C(F)(F)F)o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.39
FLT1 P17948 8/20 0.39
NPC1 O15118 2/20 0.38
KDM4E B2RXH2 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
NLRP3 Q96P20 1/20 0.35
ALDH1A1 P00352 2/20 0.34
SLC22A12 Q96S37 2/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
GSK3B P49841 2/20 0.34
DYRK3 O43781 1/20 0.33
MAP4K4 O95819 1/20 0.33
CDK1 P06493 1/20 0.33
PIM1 P11309 1/20 0.33
CDK2 P24941 1/20 0.33
FLT3 P36888 1/20 0.33
CSNK1A1 P48729 1/20 0.33
GSK3A P49840 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1418141 0.85 KDR (0.39) KDRFLT1NPC1KDM4ETDP1
SCHEMBL7988980 0.75 ALDH1A1 (0.41) ALDH1A1
SCHEMBL6780660 0.75 KDM4E (0.49) KDRFLT1NPC1KDM4EALDH1A1
SCHEMBL7977891 0.73 CYP1A2 (0.36) KDRFLT1NPC1KDM4ENLRP3
SCHEMBL6777807 0.72 NOTUM (0.48) KDRFLT1NPC1KDM4ENLRP3
SCHEMBL6780752 0.68 L3MBTL1 (0.56) KDRFLT1KDM4EALDH1A1SLC22A12
SCHEMBL6778832 0.67 NPC1 (0.56) NPC1KDM4EALDH1A1RAB9ASMN1; SMN2
SCHEMBL6779584 0.65 KDM4E (0.58) NPC1KDM4EALDH1A1RAB9ASMN1; SMN2
SCHEMBL6780880 0.65 NPC1 (0.58) NPC1KDM4EALDH1A1SLC22A12RAB9A
SCHEMBL6973287 0.64 ALDH1A1 (0.45) TDP1ALDH1A1SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 KDR 4650/4885FLT1 3760/4885NPC1 708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.